List 1 PRESCRIPTION DRUGS REQUIRING PRE-AUTHORIZATION LIBERTY HEALTH DRUG IDENTIFICATION NUMBER (DIN)
|
|
- Ethan Perkins
- 5 years ago
- Views:
Transcription
1 PRESCRIPTION DRUGS REQUIRING PRE-AUTHORIZATION List 1 ACNE THERAPY If covered person over 30 years of age approval by Liberty Health required RETIN A CR 0.01% RETIN A CR 0.025% RETIN A CR 0.05% RETIN A CR 0.1% RETIN A GEL 0.01% RETIN A GEL 0.025% RETIN_A CR 0.05% RETIN_A CR 0.1% RETIN_A GEL 0.01% RETIN_A GEL 0.025% RETIN A GEL 0.1% RETISOL A CR 0.01% RETISOL A CR 0.025% RETISOL A CR 0.05% RETISOL A CR FORTE 0.1% STIEVA-A CR 0.01% STIEVA-A CR 0.025% STIEVA-A CR 0.05% STIEVA-A FORTE CR 0.1% STIEVA-A GEL 0.01% STIEVA-A GEL 0.025% STIEVA-A GEL 0.05% STIEVA-A SOLN 0.025% STIEVA-A SOLN 0.05% STIEVAMYCIN FORTE GEL STIEVAMYCIN GEL STIEVAMYCIN MILD GEL VIT A ACID CR 0.01% VIT A ACID CR 0.025% VIT A ACID CR 0.05% VIT A ACID CR 0.1% VIT A ACID GEL 0.025% VIT A ACID GEL 0.05% VIT A ACID GEL MILD 0.01% VIT-A ACID CR 0.01% VIT-A ACID CR 0.025% VIT-A ACID CR 0.05% VIT-A ACID CR 0.1% VIT-A ACID GEL 0.025% VIT-A ACID GEL 0.05%
2 ACNE THERAPY Cont d. If covered person over 30 years of age approval by Liberty Health required VIT-A ACID GEL MILD 0.01% VITINOIN CR 0.025% VITINOIN CR 0.05% VITINOIN CR 0.1% VITINOIN GEL 0.025% AMYOTROPHIC LATERAL SCLEROSIS RILUTEK TAB 50MG ATOPIC DERMATITIS PROTOPIC OINT 0.1% PROTOPIC OINT 0.03% BOTOX BOTOX INJECTION CROHN S DISEASE REMICADE INJ IV 100MG/VL COX-2 CELEBREX CAP 100MG CELEBREX CAP 200MG VIOXX SUSP 12.5MG/5ML VIOXX TAB 12.5MG VIOXX TAB 25MG MOBICOX TAB 7.5MG MOBICOX TAB 15MG CYCLOSPORINE NEORAL CAP 10MG NEORAL CAP 25MG NEORAL CAP 50MG NEORAL CAP 100MG NEORAL CAP 100MG NEORAL LIQ NEORAL LIQ 100MG/ML NEORAL_CAP 10MG NEORAL_CAP 25MG NEORAL_CAP 50MG
3 CYCLOSPORINE Cont. SANDIMMUNE AMP 50MG SANDIMMUNE CAP 25MG SANDIMMUNE CAP 50MG SANDIMMUNE CAP 100MG SANDIMMUNE LIQ 100MG/ML SANDIMMUNE ORL SOLN 100MG SANDIMMUNE_CAP 25MG SANDIMMUNE_CAP 50MG SANDIMMUNE_CAP 100MG CYSTIC FIBROSIS COTAZYM CAP 300MG COTAZYM CAP 65B COTAZYM ECS 4 CAP COTAZYM ECS 8 CAP COTAZYM ECS 20 CAP COTAZYM PDR COTAZYM_ECS CAP COTAZYM_ECS CAP CREON 5 CAP CREON 8 CAP CREON 10 CAP CREON 20 CAP CREON 25 CAP PANCREASE CAP PANCREASE CAP MT PANCREASE MT 10 CAP PANCREASE MT 16 CAP PANCREASE EC SR CAP VIOKASE PDR VIOKASE PDR (114G) VIOKASE TAB VIOKASE_PDR VIOKASE_PDR (114GM) VIOKASE_TAB 325MG VIOKASE_TAB 325MG VIOKASE TAB VIOKASE TAB 325MG
4 CHRONIC HEPATITIS C PEG- INTRON INJ 50MCG/0.5ML PEG-INTRON INJ 80MCG/0.5ML PEG-INTRON INJ 120MCG/0.5ML PEG-INTRON INJ 150MCG/0.5ML RENAL DISEASE RENAGEL CAP 403MG RENAGEL TAB 400MG RENAGEL TAB 800MG RHEUMATOID ARTHRITIS ENBREL INJ 25MG/VIAL REMICADE INJ IV 100MG/VL KINERET TESTOSTERONE REPLACEMENT THERAPY ANDROGEL 25MG PER 2.5G GEL ANDROGEL 50MG PER 5.0G GEL ANDRODERM 12.2MG PATCH ANDRODERM 24.3 MG PATCH CHRONIC MYELOID LEUKEMIA GLEEVEC PULMONARY ARTERIAL HYPERTENSION TRACLEER 62.5MG TRACLEER 125MG FLOLAN 0.5MG/VIAL FLOLAN 1.5MG/VIAL INJECTIBLE IRON PRODUCTS INFUFER DEXIRON
5 MELANOMA MELACINE INJ KIDNEY TRANSPLANT THERAPY RAPAMUNE ORAL SOLN 1MG/ML ANTIBIOTICS ZYVOXAM TAB 600MG AGE RELATED MACULAR DEGENERATION VISUDYNE INJ 15MG VARICOSE VEIN/SCLEROSING AGENTS DEXTROJECT INJ 25% ETHANOLAMINE OLEATE INJ ETHANOLAMINE_OLEATE AMP SALIJECT SALIJECT INJ 570MG/ML SCLERODEX INJ SCLERODEX INJ 25% SCLERODEX IV INJ SCLERODINE INJ 3% SCLERODINE INJ 60MG/ML TROMBOJECT INJ 1% TROMBOJECT INJ 3% TROMBOVAR THERAPEX SOLN 1% TROMBOVAR THERAPEX SOLN 3% ANTI-EPILEPTIC DRUGS TRILEPTAL 150MG TABLETS TRILEPTAL 300MG TABLETS TRILEPTAL 600MG TABLETS TRILEPTAL 600MG/ML ORAL SUSPENSION
6 ANTI-ANEMIC DRUGS (ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE) LIBERTY HEALTH ARANESP PF SYRINGE 10MCG - 0.4ML ARANESP PF SYRINGE 20MCG - 0.5ML ARANESP PF SYRINGE 30MCG 0.3ML, MCG 0.4ML, 50MCG 0.5ML ARANESP PF SYRINGE 60MGC 0.3ML, MCG 0.4ML, 100MCG 0.5ML ARANESP PF SYRINGE 150MCG 0.3ML CHRONIC LYMPHOCYTIC LEUKEMIA FLUDARA 10MG TABLET ANTI-OBESITY XENICAL CAP 120MG MERIDIA CAP 10MG MERIDIA CAP 15MG For Xenical and Meridia, the patient s physician must complete the Weight Loss Drug Therapy Authorization Form. ********************* 6
7 List 2 LIBERTY HEALTH ANTI NEOPLASTIC THERAPY FLUDARA INJ 50MG CANCER DRUGS INTRON A 3M IU PDR INTRON A 3M IU-0.5ML VIAL INTRON A 5M IU PDR INTRON A 5M IU-0.5ML VIAL INTRON A 5M IU/ML INTRON A 10M IU PDR INTRON A 10M IU-1ML VIAL INTRON A 18M IU M-DOSE PEN KIT INTRON A 18M IU-3ML VIAL INTRON A 18M IU-KIT INTRON A 25M IU-2.5ML VIAL INTRON A 30M IU M-DOSE PEN KIT INTRON A 60M IU M-DOSE PEN KIT INTRON-A 3M IU INTRON-A 5M IU INTRON-A 10M IU INTRON-A 10M IU ROFERON A PDR 3M IU ROFERON A PDR 9M IU ROFERON A PDR 18M IU ROFERON A SOLN INJ 3M IU ROFERON A SOLN INJ 4.5M IU ROFERON A SOLN INJ 6M IU ROFERON A SOLN INJ 9M IU ROFERON A SOLN INJ 18M IU ROFERON-A INJ 36M IU ROFERON-A PDR 18M IU ROFERON-A SOLN INJ 3M IU ROFERON-A SOLN INJ 9M IU ROFERON-A SOLN INJ 18M IU STEROIDS DUE TO GROWTH HORMONE FAILURE NUTROPIN AQ INJ 10MG NUTROPIN PDR 5MG NUTROPIN PDR 10MG PROTROPIN INJ 5MG PROTROPIN INJ 10MG PROTROPIN_INJ 5MG PROTROPIN_INJ 10MG SAIZEN PDR 5MG/VIAL SAIZEN PDR 10 IU (3.3MG VIAL)
8 8
SASKATCHEWAN FORMULARY COMMITTEE BULLETIN UPDATE TO THE 54th EDITION
Saskatchewan Health Drug Plan and Extended Benefits Branch January 2005 Bulletin #101 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE BULLETIN UPDATE TO THE 54th EDITION NEW FULL FORMULARY LISTING: The
More informationQuarterly pharmacy formulary change notice
Provider update Quarterly pharmacy formulary change notice Summary: The formulary changes listed in the table below were reviewed and approved at our first-quarter 2018, Pharmacy and Therapeutics Committee
More informationQuarterly pharmacy formulary change
Medi-Cal Managed Care L. A. Care Major Risk Medical Insurance Program Provider Bulletin The formulary changes listed in the table below were reviewed and approved at our first-quarter 2018 Pharmacy and
More informationQuarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice Provider update Summary: Effective August 1, 2018, the preferred formulary changes detailed in the table below will apply to District of Columbia Healthy Families
More informationAdvantage by Peach State Health Plan 2012 Prior Authorization Listing. Approved 10/23/2011 Effective October 2011
Advantage by Peach State Health Plan 2012 Approved 10/23/2011 Effective October 2011 Note to members: The prior authorization requirements are listed to provide you with information to discuss treatment
More informationList of Designated High-Cost Drugs
List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at
More informationSpecialty conditions overview
Specialty conditions overview Prevalence and cost Click on the vials to learn more about these specialty conditions. 1. Approximate annual AWP cost per patient of top utilized drugs for UHC calendar year
More informationThese programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details.
FlexRx Standard Utilization Management (PA, QL,) Updates January 1, 2018 How to use this drug list This drug list includes updates to Utilization Management (UM) programs. UM may include a prior authorization
More informationDrug Name Tier Drug Name Tier
Drug Name Tier Drug Name Tier ABELCET 100 MG/20 ML VIAL 4 ACETYLCYSTEINE 10% VIAL 2 ACETYLCYSTEINE 20% VIAL 2 ACYCLOVIR 1,000 MG/20 ML VIAL 2 ACYCLOVIR 500 MG/10 ML VIAL 2 ADRUCIL 500 MG/10 ML VIAL 2 ALBUTEROL
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
July 1, 2017 Bulletin #166 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Recommended as a full Formulary benefit: adapalene/benzoyl peroxide, topical
More informationHEALTHTEAM ADVANTAGE PLAN 2017 Step Therapy Criteria Pending CMS Approval
ARISTADA - ARISTADA INJ 441MG/1.6 ARISTADA INJ 662MG/2.4 ARISTADA INJ 882MG/3.2 CLAIM WILL PAY AUTOMATICALLY FOR ARISTADA IF ENROLLEE HAS A PAID CLAIM FOR AT LEAST A 1 DAYS SUPPLY OF ABILIFY MAINTENA AND
More informationQuarterly pharmacy formulary change notice
Provider Bulletin April 2018 This table is used by HealthKeepers, Inc. to indicate formulary changes applicable to all Anthem HealthKeepers Plus members. These changes were reviewed and approved at the
More informationFORMULARY CHANGE NOTICE 2008 JULY
FORMULARY CHANGE NOTICE 2008 JULY Drug Name Dosage Form Strength Alternative Medicine* Formulary Formulary Change and Reason Status of Alternative Medication Updated Status On Formulary STARLIX TABS 120MG
More informationP.E.I. Drug Programs. Formulary Update. Issue June 09, 2010
P.E.I. Drug Programs Formulary Update Issue 10-01 June 09, 2010 st Effective July 1, 2010, the following medications will be added to the P.E.I. Drug Formulary. New medications for the treatment of ankylosing
More informationPip Description Item Size EAN ACETAZOLAMIDE TABS 250MG ADENOSINE INJECTION 30MG/10ML MPI 10ML
Pip Description Item Size EAN 112-6895 ACETAZOLAMIDE TABS 250MG 112 5060010283911 118-7376 ADENOSINE INJECTION 30MG/10ML MPI 10ML 6 5099602996281 118-7384 ADENOSINE INJECTION 3MG/ 1ML MPI 2ML 6 5099602996274
More informationPip Description Item Size EAN 6999 DELTASTAB INJ 25MG/1ML APRESOLINE AMP 20MG AUREOCORT OINT 15G
Pip Description Item Size EAN 6999 DELTASTAB INJ 25MG/1ML 10 5021730017613 15859 APRESOLINE AMP 20MG 5 5021730005740 21717 AUREOCORT OINT 15G 5021691164753 29033 SLOW TRASICOR TAB 160MG 28 5060064170410
More informationEmblem Medicaid 3Q18 Formulary Updates
ALKERAN 2 MG TABLET Removed from Formulary 7/9/2018 AMITIZA 24 MCG CAPSULES Removed from Formulary 7/9/2018 AMITIZA 8 MCG CAPSULE Removed from Formulary 7/9/2018 avo cream topical emulsion Removed from
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes June 2017 Effective June 29, 2017 Drug Programs Policy and Strategy Branch Ontario
More informationMagellan Rx. A smarter approach to pharmacy benefits management
Magellan Rx A smarter approach to pharmacy benefits management Presented by: Cheri Caruso, VP of Sales, Magellan Rx Management Bryce Canfield, VP, Client Development, GoodRx A unique vision of care We
More informationCircular May High Tech Hub Ordering and Management System
Feidhmeannacht na Seirbhíse Sláinte, Seirbhís Aisíocaíochta Cúraim Phríomhúil Bealach amach 5 an M50, An Bóthar Thuaidh, Fionnghlas Baile Átha Cliath 11, D11 XKF3 Guthán: (01) 864 7100 Facs: (01) 834 3589
More informationBRINTELLIX. Step Therapy Criteria HealthTeam Advantage Formulary ID: Version 6 Effective Date: 1/1/2016. PRODUCT(s) AFFECTED BRINTELLIX
BRINTELLIX BRINTELLIX Claim will pay automatically for brintellix if enrollee has a paid claim for at least a 1 days supply of any 2 generic formulary antidepressants in the past 365 days. Otherwise, brintellix
More informationHOW TO USE THE FORMULARY
INTRODUCTION The information contained in the Willamette Valley Community Health (WVCH) WRAP/D-Excluded Formulary and its appendices is provided solely for the convenience of medical providers. WVCH does
More informationSASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY
Saskatchewan Health Drug Plan and Extended Benefits Branch April 2006 Bulletin #106 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY All
More informationAspirin. Iron Supplements
Interim Final Rules for Non-Grandfathered Group Health Plans and Health Insurance Issuers Coverage of Preventive Services Under the Patient Protection and Affordable Care Act Aspirin Aspirin to Prevent
More informationPrescription Drug Benefit Rider V
Prescription Drug Benefit Rider V Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
More informationBENEFIT CHANGES TO NBPDP
Bulletin #789 June 15, 2010 BENEFIT CHANGES TO NBPDP This update to the New Brunswick Prescription Drug Program (NBPDP) Formulary is effective June 15, 2010. Included in this bulletin: Regular Benefit
More informationLIST OF DRUGS DURING 2004
LIST OF DRUGS DURING 2004 S.NO Name Of Drug Pharmacological Classification Date of Approval 188 Dutasteride For BPH 16-02-2004 189 Gefitinib Anti-cancer 17-02-2004 190 Imidapril Anti-hypertensive 23-02-2004
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes December 2018 Effective December 21, 2018 Drug Programs Policy and Strategy Branch
More informationLIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT
LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT The following medications may be covered under your medical benefit if they are provided to you in your doctor s office or outpatient infusion
More informationDescriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin
Self-Administered Drug Exclusion List R2 This article from Medicare A News, Issue 2106 dated January 23, 2013 and Medicare B News, Issue 283 dated January 23, 2013 is being revised to add Acthar ACTH gel
More informationSASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN 51st Edition
Saskatchewan Health Drug Plan and Extended Benefits Branch July, 2002 Bulletin #91 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN 51st Edition NEW LISTINGS NEW EXCEPTION DRUG STATUS AGENT
More informationSASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN 52nd Edition
Saskatchewan Health Drug Plan and Extended Benefits Branch April, 2003 Bulletin #94 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN 52nd Edition NEW EXCEPTION DRUG STATUS AGENTS Effective
More informationACYCLOVIR OINT (CCHP2017)
ACYCLOVIR OINT (CCHP2017) acyclovir 5 % topical ointment Step Therapy requires trial of one (1) of the following: oral generic acyclovir, oral generic famciclovir, oral generic valacyclovir. 1 ALPHAGAN
More informationPRESCRIPTION DRUG PROGRAM FORMULARY UPDATES
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Generic Additions These generic drugs recently became available in the marketplace. When these generic drugs became available, we began covering them at the
More information2018 Formulary Notice of Change Prescription Drug Plans
2018 Formulary Notice of Change Prescription Drug Plans WellCare Prescription Insurance, Inc. Plans in all states: WellCare Classic (PDP) WellCare may add or remove drugs from our formulary during the
More informationRAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)
INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationCystic Fibrosis Agents
Texas Prior Authorization Program Clinical Criteria Clinical Information Included in this Document Kalydeco (Ivacaftor) Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationHealth Partners Medicare Prime 2019 Formulary Changes
Health Partners Medicare Prime 2019 Formulary Changes Changes occur, for example, because new drugs come on the market, a drug is moved to a different cost-sharing level (tier), or a generic version becomes
More informationCystic Fibrosis Agents
Texas Prior Authorization Program Clinical Criteria Clinical Information Included in this Document Kalydeco (Ivacaftor) Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationPrice Changes advised by Pharmac As at 12 June 2015
s advised by Pharmac New to be available ex Manufacturer from 12th of preceding month. From Wholesale from date of supplier support which could vary. Product Supplier Schedule % + or - 01 Jun 15 31 Oct
More informationPrescription Drug Benefit Rider
Prescription Drug Benefit Rider Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your
More informationQuarterly pharmacy formulary change notice
Provider Bulletin October 2018 Quarterly pharmacy formulary change notice The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. The changes listed in the table
More informationQuarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice Provider update Summary: The formulary changes listed in the table below were reviewed and approved at our second quarter 2018, Pharmacy and Therapeutics Committee
More information2015 Chinese Community Health Plan Senior Program (HMO) Step Therapy Criteria Last Updated 11/1/2015
2015 Chinese Community Health Plan Senior Program (HMO) Step Therapy Last Updated 11/1/2015 APLENZIN TAB 174MG, 348MG, 522MG Step Therapy requires trial of bupropion SR or bupropion XL in previous 180
More informationACYCLOVIR OINT (CCHP2017)
ACYCLOVIR OINT (CCHP2017) acyclovir 5 % topical ointment Step Therapy requires trial of one (1) of the following: oral generic acyclovir, oral generic famciclovir, oral generic valacyclovir. 1 ALPHAGAN
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - July 2014 Effective July 30, 2014 Ministry of Health and Long-Term Care Table of Contents New Single Source Products...
More informationBiologic Immunomodulators Prior Authorization with Quantity Limit Program Summary
Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the
More informationTretinoin Cream Reviews For Acne Scars
Tretinoin Cream Reviews For Acne Scars tretinoin gel usp 0.1 reviews tretinoin cream.025 review generic tretinoin cream cost tretinoin gel 0.025 tretinoin gel 0.05 20g generic where to buy tretinoin cream.025
More informationNotice of Mid-Year Changes to 2019 Paramount Enhanced Formulary
Notice of Mid-Year s to 2019 Paramount Enhanced Formulary Paramount Elite (HMO) may immediately remove a brand name drug on our List if we are replacing it with a new generic drug that will appear on the
More informationInjectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Injectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH) Clinical Edit Information Included in this Document
More informationPegylated Interferons and Ribavirins
Pegylated Interferons and Ribavirins Goal(s): Cover drugs only for those clients where there is evidence of effectiveness and safety Length of Authorization: 16 weeks plus 12-36 additional weeks or 12
More informationQuarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice Summary of change: The Pharmacy and Therapeutics Committee (P&T) reviewed and approved the formulary changes listed in the table below on March 29, 2016. What
More informationLECOM Health Ophthalmology
Patient Name: Date of Birth: New Patient Questionnaire Your answers will be used by your healthcare provider get an accurate history of your medical conditions and ocular concerns. If you are uncomfortable
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationQuarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice The formulary changes listed in the table below were reviewed and approved at our second quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October
More information2018 CareOregon Advantage Part D Formulary Changes
2018 CareOregon Advantage Part D Formulary Changes Abbreviations: AGE = Age Restriction; PA = Prior Authorization Required; QL = Quantity Limit; ST = Step Therapy Required; LD = Limited Distribution; BvD
More informationQuarterly pharmacy formulary change notice
MEDICAID PROVIDER BULLETIN March 2019 Quarterly pharmacy formulary change notice The formulary changes listed in the table below were reviewed and approved at the fourth quarter pharmacy and therapeutics
More informationPlan Year CCHP Senior Program (HMO) Step Therapy Criteria (ST)
Plan Year 2016 CCHP Senior Program (HMO) Step Therapy Criteria (ST) Step Therapy: In some cases, CCHP Senior Program (HMO) requires you to first try certain drugs to treat your medical condition before
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
April 1, 2018 Bulletin #169 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Recommended as a full Formulary benefit: benztropine mesylate, tablet,
More informationSASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY
Saskatchewan Health Drug Plan and Extended Benefits Branch October 2005 Bulletin #104 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY All
More informationPharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 04/15/2015 Effective date: 05/15/2015 Therapeutic Classes reviewed: Testosterone replacement
More informationApproximate Cost for Patients
Insurance Coverage for Prescriptions Medications that enhance control of pain and symptoms may be costly if patients do not have insurance. In Ontario, the Ontario Drug Benefit (ODB) Program covers prescriptions
More informationMediscor Medicines Review 2011
Mediscor Medicines Review 2011 Mediscor Client Workshop 2012 28 August 2012 Presented by: Madelein Bester Benefit Management Mediscor PBM Content Background of the report Overall trends Expenditure per
More informationCase Name NDC Company Case Size Type Order Qty.
Name NDC Company Size Type Order ACI-JEL 85 GM 0062542101 Janssen Pharmaceuticals, 12 12 0.00 ACIPHEX 20MG 10X10X24 HUD 6285624341 Eisai 24 24 0.00 ACIPHEX 20MG 30X48 Bottles 6285624330 Eisai 48 48 0.00
More informationAZITHROMYCIN AND PREDNISONE FOR BRONCHITIS
AZITHROMYCIN AND PREDNISONE FOR BRONCHITIS Azithromycin And Prednisone For Bronchitis Ampicillin and azithromycin for h pylori treatment Azithromycin 200mg/5ml oral susp Does cvs sell azithromycin Spirits
More informationQuarterly pharmacy formulary change notice
MEDICAID PROVIDER BULLETIN October 2018 The formulary changes listed in the table below were reviewed and approved at the second-quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October
More informationChanges to the 2018 BlueCross Secure SM (HMO) & BlueCross Total SM (PPO) Formularies
Changes to the 2018 BlueCross Secure SM (HMO) & BlueCross Total SM (PPO) Formularies BlueCross BlueShield of South Carolina may add or remove drugs from the formulary during the year. If we remove drugs
More informationNew Exception Status Benefits
AUGUST 2017 Nova Scotia Formulary Updates New Exception Status Benefits Forxiga (dapagliflozin) Xigduo (dapagliflozin and metformin hydrochloride) Criteria Update: Antipsychotic Medications Abilify (aripiprazole)
More informationCHRONIC TREATMENT GUIDELINES
CHRONIC TREATMENT GUIDELINES REGISTRATION OF CHRONIC CONDITIONS You can only access benefits for chronic medication, as listed below, if your prescribing/treating doctor or pharmacist registers your chronic
More informationLET S TALK PREVENTION
LET S TALK PREVENTION YOUR NO-COST PRESCRIPTION DRUGS FOR PREVENTIVE CARE Your health plan offers certain preventive service benefits at no cost to you. This means you don t have to pay a copay* or coinsurance,
More information1, 2014 PHARMACY BENEFIT
Effective 01/01/2007City of Plano Employee Benefit Design Summary Effective Date: January 1, 2014 PHARMACY BENEFIT CVS/CAREMARK TOLLFREE: 888-850-8245 ID CARD & NETWORK PHARMACIES: Identification Card
More informationUPDATE F Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective 30 January, 2009 SUMMARY OF CHANGES
UPDATE F Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective 30 January, 2009 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 3 Manufacturer
More informationMDwise Self-Administered Codes for Medical
The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively
More informationTretinoin Cream.025 Acne
Tretinoin Cream.025 Acne 1 tretinoin cream 1 percent 2 tretinoin cream.025 acne scars 3 is tretinoin cream available over the counter 4 tretinoin cream 0.1 directions use 5 buy tretinoin 6 tretinoin cream
More informationSASKATCHEWAN FORMULARY COMMITTEE BULLETIN 55th EDITION
Saskatchewan Health Drug Plan and Extended Benefits Branch July 2005 Bulletin #103 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE BULLETIN 55th EDITION All listings are effective July 1, 2005 NEW FULL
More information2019 Supplemental Drug List
2019 Supplemental Drug List This supplemental drug list was updated on August 2018. For more recent information or other questions, please contact Blue Cross Medicare Advantage Customer Service, at 1-877-299-1008
More informationNetwork Health Insurance Corporation Upcoming Negative Changes to the Medicare Part D Formulary
Requesting an Exception to the Formulary You can ask Network Health Insurance Corporation to make an exception to our coverage rules. Generally, we will only approve your request for an exception if alternative
More informationDrugs approved from 1st January 2015 till present. S.NO Name Of Drug Indication Date of Approval 1 Levocetirizine ODS 2.5mg /5mg (Additional
Drugs approved from 1st January 2015 till present S.NO Name Of Drug Indication Date of 1 Levocetirizine ODS 2.5mg /5mg dosage form) For allergic rhinitis and chronic urticaria. 14.01.15 2 Decitabine Injection
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 18, 2016 Xeljanz Description Xeljanz, Xeljanz
More informationYour DISPENSARY Tips as at 26 November 2015
This information has been prepared to provided some essential buying tips for the upcoming months. It is designed to be used in conjunction with the full text documents contained within the Pharmac Updates
More informationDrug Formulary. A healthier you. A healthier community.
Drug Formulary This Formulary is up to date through its date of publication, November 2, 2016. Please contact NextLevel Health at 1.844.807.9734 or info@nlhpartners.com with any mistakes in the formulary.
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018
January 201 DATE DAY TIME TOPICS TOTAL January 04 1. Understanding Fibromyalagia 2. Diabetes and Cardiovascular Disease 3. Prostate Cancer 4. Hepatitis C 5. Understanding Hepatitis B January 11 1. Dysphagia
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class COX-2 Inhibitors Clinical Edit Information Included in this Document COX-2 Inhibitors Celebrex Drugs requiring prior authorization:
More informationMedicare Part D 2016 Formulary Changes Service To Senior and OC Preferred
Medicare Part D 2016 Formulary s Service To Senior and OC Preferred Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior
More informationDrug Schedule For RC 143(A)
DRUGS FOR RESPIRATORY SALBUTAMOL TAB - Each Tab to SYSTEM 1 30a contain:salbutamol 2mg. 1 tab 9600000 100000 200000 SALBUTAMOL TAB - Each Tab to 2 30b contain:salbutamol 4 mg. 1 tab 8000000 80000 160000
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2019
January 2019 DATE DAY TIME TOPICS TOTAL January 03 1. Alcoholism 2. Nutrition for the Elderly 3. Uterine Fibroids 4. HIPAA 5.Arthritis 6. Childhood Obesity January 10 1. Understanding Epilepsy: Latest
More informationNeighborhood Medicaid Formulary Changes: June 2017
Neighborhood Medicaid Formulary Changes: June 2017 The following changes to the Neighborhood Medicaid Formulary were recently approved by the Pharmacy and Therapeutics (P&T) Committee. All changes were
More informationEVIDENCE-BASED VITAMIN AND MINERAL USAGE SUMMARY TABLE (APRIL 2002)
Acne Acrodermatitis Enteropathica Adrenal Support Age Related Cognitive Decline Alcoholism/Alcohol Withdrawal Alzheimer's Disease Amenorrhoea Anaemia Angina Anorexia Nervosa Anxiety Asthma Atherosclerosis
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 17, 2017 Xeljanz Description Xeljanz, Xeljanz
More informationSCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs. January 2018 WALK INS ARE ACCEPTED BUT WE ADVISE STUDENTS TO PRE-REGISTER BEFORE THURSDAY
SCHEDULE OF CONTINUING EDUCATION COURSES FOR RN s and CNAs January 201 DATE DAY TIME TOPICS January 04 January 11 January 1 January 25 9:00AM 9:00AM 9:00AM 9:00AM 1. Understanding Fibromyalagia 2. Diabetes
More informationSASKATCHEWAN FORMULARY BULLETIN. Update to the 60th Edition of the Saskatchewan Formulary
Saskatchewan Ministry of Health July 1, 2010 Drug Plan and Extended Benefits Branch Bulletin #124 ISSN 1923-077X SASKATCHEWAN FORMULARY BULLETIN Update to the 60th Edition of the Saskatchewan Formulary
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationQuarterly pharmacy formulary change notice
Provider Bulletin June 24, 2016 Summary of change The Pharmacy and Therapeutics Committee reviewed and approved the formulary changes listed in the table below on March 29, 2016. What this means to you
More informationUPDATE B Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 01, 2008 SUMMARY OF CHANGES
UPDATE B Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 01, 2008 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Multi-Source Drug(s) 2 Manufacturer Requested Discontinued
More information2010 Drugs Requiring Prior Authorization
2010 Drugs Requiring Prior Authorization Drugs Covered Uses Exclusion Criteria Actemra (tocilizumab) Adcirca (tadalafil) Alfa Interferons - Alferon N - Infergen - PEG-Intron - PEG-Intron Redipen - Pegasys
More informationOntario Drug Benefit Formulary/ Comparative Drug Index
Ontario Drug Benefit Formulary/ Comparative Drug Index Edition 42 Summary of Changes January 2014 Effective January 30, 2014 Ministry of Health and Long-Term Care Table of Contents Additions to Formulary...
More information